Bafna Pharmaceuticals Ltd
Bafna Pharmaceuticals Ltd (BAFNAPH) last traded at ₹272, a market capitalisation of ₹644 crore. Over the past 52 weeks the stock has ranged between ₹94.8 and ₹296. Bafna Pharmaceuticals Ltd last reported results for the quarter ended Sep 2019, with sales of ₹11.57 crore and net profit of ₹-0.59 crore. Bafna Pharmaceuticals Ltd’s annual general meeting is scheduled for 11 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Bafna Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Bafna Pharmaceuticals Ltd quarterly results
| ₹ crore | Jun 2018 | Sep 2018 | Jun 2019 | Sep 2019 |
|---|---|---|---|---|
| Sales | 11.95 | 8.84 | 6.85 | 11.57 |
| Expenses | 13.77 | 8.66 | 9.71 | 11.95 |
| Operating profit | -1.82 | 0.18 | -2.86 | -0.38 |
| OPM % | -15.23% | 2.04% | -41.75% | -3.28% |
| Other income | 0.09 | -0.03 | 0.3 | 0.59 |
| Interest | 0.83 | 0.62 | 0.13 | 0.04 |
| Depreciation | 1 | 0.75 | 1.02 | 0.72 |
| Profit before tax | -3.56 | -1.22 | -3.71 | -0.55 |
| Tax % | -1.12% | 4.10% | -42.59% | 7.27% |
| Net profit | -3.52 | -1.28 | -2.13 | -0.59 |
| EPS (₹) | -1.49 | -0.54 | -0.90 | -2.49 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Bafna Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 |
|---|---|---|---|---|---|---|
| Sales | 97 | 85 | 65 | 46 | 44 | 42 |
| Operating profit | -18 | 1 | -6 | -35 | -13 | 1 |
| OPM % | -18% | 0.6% | -9% | -77% | -30% | 2.9% |
| Net profit | 6 | -15 | -19 | -17 | -18 | -24 |
| EPS (₹) | 3.31 | -7.52 | -10.23 | -7.08 | -7.98 | -104.54 |
TTM is the trailing twelve months to the most recent quarter.
Bafna Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- -15%
- 3 Years
- -13%
- TTM
- -3%
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 24%
- TTM
- 89%
- 10 Years
- 25%
- 5 Years
- 13%
- 3 Years
- 33%
- 1 Year
- 166%
- 10 Years
- %
- 5 Years
- -45%
- 3 Years
- -64%
- Last Year
- -6%
Bafna Pharmaceuticals Ltd shareholding pattern
Promoters held 75.00% at Jun 2026, broadly unchanged since Jun 2025. FIIs 9.34%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 88.29% | 88.29% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FIIs | 0.00% | 0.00% | 8.53% | 9.34% | 9.34% | 9.34% | 9.34% | 9.34% |
| Public | 11.70% | 11.70% | 16.47% | 15.66% | 15.66% | 15.66% | 15.66% | 15.66% |
| No. of shareholders | 7,295 | 7,214 | 7,142 | 7,283 | 7,572 | 7,119 | 6,928 | 7,062 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Bafna Pharmaceuticals Ltd’s AGM?
Bafna Pharmaceuticals Ltd’s annual general meeting is scheduled for 11 Sept 2026.
- AGM31st Annual General Meeting
See the full results calendar for every Indian company reporting in the next 30 days.
Bafna Pharmaceuticals Ltd corporate filings
- We herewith enclose the Newspaper Publication for the 31st Annual General Meeting of the Company published in ''Business Standard'' and ''Makkal Kural'' on August 20, 2026.Company Updatelow impact
Cruxal's analysis: Bafna Pharmaceuticals has published the notice for its 31st Annual General Meeting in…
Read the full analysis - We herewith enclose the Notice of 31st Annual General Meeting of the Company scheduled to be held on Friday, September 11, 2026 at 10.00 A.M along with the Annual Report of the Company ....AGM/EGMhigh impact
Cruxal's analysis: Bafna Pharmaceuticals Limited has released its Annual Report for FY 2025-26, showcasing…
Read the full analysis - We herewith enclose the Annual Report of the Company for the F.Y 2025-2026.Otherslow impact
Cruxal's analysis: Bafna Pharmaceuticals has submitted its Annual Report for the financial year 2025-2026 as…
Read the full analysis - Newspaper Publication for the Unaudited Financial Results of the Company for the Quarter ended June 30, 2026 as published in ''Business Standard'' and ''Makkal Kural'' on August 13, 2026.Company Updatelow impact
Cruxal's analysis: Bafna Pharmaceuticals Limited has released its unaudited financial results for the…
Read the full analysis - We herewith enclose the intimation for Book Closure and Cut-Off dates for the purpose of 31st Annual General Meeting of the Company.Corp. Actionlow impact
Cruxal's analysis: Bafna Pharmaceuticals has issued an intimation regarding the book closure and cut-off…
Read the full analysis - We hereby inform that the 31st Annual General Meeting (AGM) of the Company is scheduled to be held on Friday, September 11, 2026 at 10.00 A.M through Video Conferencing (VC) / Other Audio ....AGM/EGMlow impact
Cruxal's analysis: Bafna Pharmaceuticals Limited has announced that its 31st Annual General Meeting will be…
Read the full analysis - We hereby inform you that the Board of Directors in their meeting held on August 11, 2026 inter-alia considered and approved i) Unaudited Financial Results of the Company for the Quarter ....Board Meetinghigh impact
Cruxal's analysis: Bafna Pharmaceuticals Limited reported a sharp decline in financial performance for the…
Read the full analysis - Bafna Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the Un-Audited Financial ....Board Meetinglow impact
Cruxal's analysis: Bafna Pharmaceuticals Limited has issued a formal intimation regarding a Board of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Bafna Pharmaceuticals Ltd
Cruxal reads every Bafna Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.